Uqva3rjxqkcn4kaahzie irdn3

iRND3, Institute for Rare and Neglected Diseases Drug Discovery

No Reviews Yet
1 Order Completed
Mountain View, California, US

About iRND3, Institute for Rare and Neglected Diseases Drug Discovery

iRND3 is a 501c3, non-profit research organization that conducts pre-clinical drug discovery research to help discover medicines for rare and neglected diseases.

iRND3 looks to satisfy its charitable mission through the collaborative discovery of medicines for rare and neglected diseases.

iRND3 has a well... Show more »

iRND3 is a 501c3, non-profit research organization that conducts pre-clinical drug discovery research to help discover medicines for rare and neglected diseases.

iRND3 looks to satisfy its charitable mission through the collaborative discovery of medicines for rare and neglected diseases.

iRND3 has a well equipped lab in Mountain View, CA

iRND3 works to fund its mission through grants, donations and fee for service research.

iRND3's current disease focus is on trypanosome diseases and rare cancers.

iRND3's technical expertise is in the areas of drug discovery screening strategies, optimal molecule mechanism of action (MMOAs), binding kinetics, enzymology and assay development.

Recent Publications

  • A Four-Point Screening Method for Assessing Molecular Mechanism of Action (MMOA) Identifies Tideglusib as a Time-Dependent Inhibitor of Trypanosoma brucei GSK3β. Swinney ZT, Haubrich BA, Xia S, Ramesha C, Gomez SR, Guyett P, Mensa-Wilmot K, Swinney DC. PLoS Negl Trop Dis. 2016 Mar 4;10(3):e0004506. doi: 10.1371/journal.pntd.0004506. eCollection 2016.
  • Enzyme activity assays for protein kinases: Strategies to identify active substrates. Haubrich BA, Swinney DC. Curr Drug Discov Technol. 2016 Jan 15.
  • Drug Discoveries and Molecular Mechanism of Action. David C. Swinney. Successful Drug Discovery, Wiley-VCH (2015)
  • Kinetics and Thermodynamics of Drug Binding. GM Keserü, DC Swinney ed Wiley-VCH , Weinheim, Germany 2015
  • How medicines for rare diseases were discovered? Swinney DC & Xia S. Frontiers Med Chem 6, 987-1002(2014)
  • Collaboration for rare disease drug discovery research. Litterman NK, Rhee M, Swinney DC, Ekins S. F1000Res. 3:261 (2014)
  • A study into the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands. Swinney DC, Beavis P, Chuang KT, Zheng Y, Lee I, Gee P, Deval J, Rotstein DM, Dioszegi M, Ravendran P, Zhang J, Sankuratri S, Kondru R, Vauquelin G. Br J Pharmacol. 171:3364-3375 (2014)
  • The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance. JSelen A, Dickinson PA, Müllertz A, Crison JR, Mistry HB, Cruañes MT, Martinez MN, Lennernäs H, Wigal TL, Swinney DC, Polli JE, Serajuddin AT, Cook JA, Dressman JB. Pharm Sci.103:3377-97 (2014)
  • The value of translational biomarkers to phenotypic assays. Swinney DC. Frontiers Pharmacol 15:171(2014)
Show less

Diversity Certificates

Small business

Our Services (9)


ic

Drug Discovery Consulting

Price on request

We provide consulting in drug discovery strategies and screening strategies. We will work closely with you to help you identify and implement strategies that will help you reach your goals.

We provide consulting in drug discovery strategies and screening strategies. We will work closely with you to help you identify and implement strategies that will help you reach your goals.

Show less

ic

Drug Mechanism of Action Studies

Mechanism of Action Studies
Price on request

We have expertise to evaluate the pharmacological and biochemical mechanisms of action of compounds at specific targets. This includes characterization of binding mechanism (competitive, noncompetitive, uncompetitive, allosteric) and binding kinetics (time-dependence).

We have expertise to evaluate the pharmacological and biochemical mechanisms of action of compounds at specific targets. This includes characterization of binding mechanism (competitive, noncompetitive, uncompetitive, allosteric) and binding kinetics (time-dependence).

Show less

ic

Cell-Based Compound Screening

Price on request

We have liquid handling, detection and data analysis software to run focused screens on targets and cells. We have experience in transforming your screen to our system and setting up robust follow-up paradigms.

We have liquid handling, detection and data analysis software to run focused screens on targets and cells. We have experience in transforming your screen to our system and setting up robust follow-up paradigms.

Show less

ic

Assay Development

Price on request

We have assays for kinases, NMNat, isolated mitochondria function and cell viability currently running. We have a great deal of experience establishing specific assays and screens. Please enquire if have a protein or system in which you would like to have an assay established, validated and screened.

We have assays for kinases, NMNat, isolated mitochondria function and cell viability currently running. We have a great deal of experience establishing specific assays and screens. Please enquire if have a protein or system in which you would like to have an assay established, validated and screened.

Show less

ic

Drug Discovery

Price on request
Request a quote for more information about this service.

ic

Project Management

Price on request
Request a quote for more information about this service.

ic

Medicinal Chemistry

Price on request
Request a quote for more information about this service.

ic

Hit Identification

Price on request
Request a quote for more information about this service.

ic

Drug Discovery & Development

Price on request
Request a quote for more information about this service.

Not finding what you're looking for?

Get info on this provider's capabilities without requesting a quote.

iRND3, Institute for Rare and Neglected Diseases Drug Discovery has not received any reviews.

iRND3, Institute for Rare and Neglected Diseases Drug Discovery has not received any endorsements.